While the inhibition of both AChE and BACE-1 is potentially desirable for the purpose of treating Alzheimer’s disease, it should be noted that problems have been encountered in clinical trials with BACE-1 as the target [36], suggesting that the analog 2 might still have relevance in the context of an Alzheimer’s treatment. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.